Ashland lowers FY26 revenue view to $1.84B-$1.87B from $1.84B-$1.91B

Consensus $1.85B. Lowers FY26 adjusted EBITDA view to $385M-$400M from $400M-$420M. The company said, “Ashland (ASH) is updating its full-year fiscal 2026 sales guidance to a range of $1,835 to $1,870 million and its Adjusted EBITDA guidance to a range of $385 to $400 million. The updated outlook reflects productivity challenges associated with the Hopewell scale-up, as well as softer energy-related demand tied to the Middle East conflict and reduced EV driven demand for BDO based derivatives. These impacts are partially offset by resilient demand in core end markets, ongoing pricing actions, and continued growth across the globalize and innovate platforms. Despite a mixed macroeconomic backdrop, Ashland’s core Personal Care and Life Sciences end markets continue to show resilience, underpinned by stable fundamentals and sustained momentum in innovation-led and globalized product offerings. Second quarter sales trends were encouraging, reflecting solid momentum across several consumer-focused markets, with early third quarter activity showing a continuation of this commercial strength. While cost-savings initiatives remain in progress, a slower-than-anticipated productivity ramp-up associated with the Hopewell HEC manufacturing site is delaying the pace of benefit realization. Ashland continues to expect the year to follow a typical seasonal cadence, with stronger performance anticipated in the second half as commercial activity builds and operational stability improves.”